Clinical Trials Browser

INDUSTRY × vedolizumab × Clear all

NCT06646016 2025-12-26

EPIC

Phase 2 Withdrawn

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Phase 1 Terminated

22 enrolled 14 charts

Melanoma